Global approaches to genomic medicine implementation.

Sci Transl Med

Andrea Belcher is at the Australian Genomics Health Alliance, Melbourne, VIC 3052, Australia, and the Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.

Published: September 2020

A snapshot of large-scale genomic medicine implementation initiatives worldwide illustrates similarities in policy considerations.

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aax0911DOI Listing

Publication Analysis

Top Keywords

genomic medicine
8
medicine implementation
8
global approaches
4
approaches genomic
4
implementation snapshot
4
snapshot large-scale
4
large-scale genomic
4
implementation initiatives
4
initiatives worldwide
4
worldwide illustrates
4

Similar Publications

Mycobacterium tuberculosis (M. tuberculosis) and Mycobacterium abscessus (M. abscessus) are important pathogens that can cause lung diseases.

View Article and Find Full Text PDF

The short-chain fatty acids (SCFAs) propionate and butyrate have beneficial health effects, are produced in large amounts by microbial metabolism and have been identified as unique acyl lysine histone marks. To better understand the function of these modifications, we used chromatin immunoprecipitation followed by sequencing to map the genome-wide location of four short-chain acyl histone marks, H3K18pr, H3K18bu, H4K12pr and H4K12bu, in treated and untreated colorectal cancer (CRC) and normal cells as well as in mouse intestines in vivo. We correlate these marks with open chromatin regions and gene expression to access the function of the target regions.

View Article and Find Full Text PDF

Nocturnal urination frequency is associated with sleep blood pressure (BP). However, it was uncertain to what extent the sleep BP increases within individuals with each increase in the number of nocturnal urination. We calculated intraindividual differences in sleep BP between nights with different urination frequencies to clarify their relationship.

View Article and Find Full Text PDF

Immune checkpoint inhibitors can lead to 'exceptional', durable responses in a subset of persons. However, the molecular basis of exceptional response (ER) to immunotherapy in metastatic clear cell renal cell carcinoma (mccRCC) has not been well characterized. Here we analyzed pretherapy genomic and transcriptomic data in treatment-naive persons with mccRCC treated with standard-of-care immunotherapies: (1) combination of programmed cell death protein and ligand 1 (PD1/PDL1) and cytotoxic T lymphocyte-associated protein 4 inhibitors (IO/IO) or (2) combination of PD1/PDL1 and vascular endothelial growth factor (VEGF) receptor inhibitors (IO/VEGF).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!